Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 2 October 1996
Like the other Techtides being developed by Diatide, P483H is a proprietary combination of synthetic peptides designed to attach themselves to targeted disease molecules and technetium-99m, a radioactive material easily detected by the gamma cameras now used by hospitals throughout the U.S. Unlike agents currently used for the detection of infections, the use of P483H as a targeting agent is an in vivo procedure requiring a single injection and no removal of blood from the patient. This is an important safety consideration in cases involving AIDS and hepatitis.
The first of the thirty patients expected to be enrolled in the Phase II trials was injected on Wednesday, September 25. The trials will be conducted at six hospitals, all patients will have documented infections, and the results will be compared to the results produced by the diagnostic procedures ordinarily used at those hospitals. Current procedures include the imaging of labeled white blood cells after removal and separation from the patient's blood, ultrasound, and x-ray.
Richard T. Dean, Ph.D., President and Chief Executive of Diatide, said completion of the Phase II trial is currently scheduled for the first quarter 1997. The Phase II results will provide a basis for the development of a protocol for a Phase III trial to be proposed to the U.S. Food and Drug Administration, he said.
Diatide estimates that approximately two million procedures for the detection of sources of internal infection are conducted in the U.S. annually, and that the worldwide market for imaging agents used in such procedures could total well in excess of $100 million per year.
Founded in 1990, Diatide conducts most of its research and development activities in New Hampshire and has 48 employees including 10 Ph.D.s and one M.D. on its research staff.
To receive additional information on Diatide, Inc., via fax, at no charge, dial 1-800-PRO-INFO and enter code DITI.
This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results that differ materially from those indicated by such forward-looking statements are set forth under the captain "Risk Factors" in the Company's Prospectus dated June 13, 1996 which is part of the Company's registration statement on file with the Securities and Exchange Commission. These Risk Factors are incorporated herein by reference. As more fully described in the Risk Factors, the Company's potential products are at an early stage of development and the results obtained in pre-clinical and clinical studies may not be indicative of results that will be obtained in later clinical trials, there can be no assurance that the Company will receive regulatory approvals to commence or continue clinical trials of product candidates or that delays in the completion of clinical trials as a result of delays in patient enrollment or other factors will not occur, and there can be no assurance that the Company will receive regulatory approvals to market any products or, if such approvals are received, that the Company's products will be commercially successful or that technologies and proposed products of other companies will not render the Company's products obsolete or noncompetitive.
CONTACT: Richard T. Dean, Ph.D., President & CEO of Diatide, 603-437-8970; or General Info: Jerry Meyer, 212-661-8030, Analyst Info: Brian Gill, 212-661-8030, Media Info: Judith Sylk-Siegel, 212-661-8030, all of The Financial Relations Board
Copyright (c) 1996/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
961002
PR961004
Copyright © 1996 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .